Asset Details
Do you wish to reserve the book?
Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine
Do you wish to request the book?
Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine
2020
Overview
As the world is severely affected by COVID-19 pandemic, the use of chloroquine and hydroxychloroquine in prevention or for the treatment of patients is allowed in multiple countries but remained at the center of much controversy in recent days. This review describes the properties of chloroquine and hydroxychloroquine, and highlights not only their anti-viral effects but also their important immune-modulatory properties and their well-known use in autoimmune diseases, including systemic lupus and arthritis. Chloroquine appears to inhibit
SARS virus' replication and to interfere with SARS-CoV2 receptor (ACE2). Chloroquine and hydroxychloroquine impede lysosomal activity and autophagy, leading to a decrease of antigen processing and presentation. They are also known to interfere with endosomal Toll-like receptors signaling and cytosolic sensors of nucleic acids, which result in a decreased cellular activation and thereby a lower type I interferons and inflammatory cytokine secretion. Given the antiviral and anti-inflammatory properties of chloroquine and hydroxychloroquine, there is a rational to use them against SARS-CoV2 infection. However, the anti-interferon properties of these molecules might be detrimental, and impaired host immune responses against the virus. This duality could explain the discrepancy with the recently published studies on CQ/HCQ treatment efficacy in COVID-19 patients. Moreover, although these treatments could be an interesting potential strategy to limit progression toward uncontrolled inflammation, they do not appear
sufficiently potent to control the whole inflammatory process in COVID-19, and more targeted and/or potent therapies should be required at least in add-on.
Publisher
Frontiers Media SA,Frontiers,Frontiers Media S.A
Subject
/ Acids
/ Angiotensin-Converting Enzyme 2
/ Antigens
/ Antiviral Agents - therapeutic use
/ Betacoronavirus - physiology
/ Coronavirus Infections - drug therapy
/ Coronavirus Infections - epidemiology
/ Coronavirus Infections - immunology
/ COVID-19
/ Drugs
/ Humans
/ Hydroxychloroquine - therapeutic use
/ Ligands
/ Lupus
/ Malaria
/ Peptidyl-Dipeptidase A - immunology
/ Pneumonia, Viral - drug therapy
/ Pneumonia, Viral - epidemiology
/ Pneumonia, Viral - immunology
/ Proteins
/ Sensors
/ Severe acute respiratory syndrome coronavirus 2
/ Systemic lupus erythematosus
/ TLR
/ Toll-Like Receptors - immunology
/ Toxicity
